Hizentra

Hizentra 200mg/ml Solution for Subcutaneous Injection, Human Normal Immunoglobulin is indicated for:

Replacement therapy in adults, children and adolescents (0-18 years) in:

• Primary immunodeficiency syndromes with impaired antibody production.
• Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of < 4 g/l.

*PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines.

Immunomodulatory therapy in adults, children and adolescents (0-18 years):

• Hizentra is indicated for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with IVIg.

Hizentra is available in the following presentations:

• 1g in 5ml vial
• 2g in 10ml vial
• 4g in 20ml vial

For details on Hizentra at Home, our homecare services programme please click here.

Please visit our Privigen page for information on our Solution for Infusion, Human Normal Immunoglobulin.

Method of Sale: POM

License Number: EU/1/11/687/001, EU/1/11/687/004 & EU/1/11/687/010

MAH Holder: CSL Behring GmbH

Emil-von-Behring-Strasse 76

D-35041 Marburg

Germany

For any further information please speak to your local Fannin Representative or contact our medical information department for a copy of the SPC at medical@dccvital.com or via phone on 01 2907000. 

Hizentra is distributed in Ireland by Fannin Ltd. in partnership with CSL Behring.  (This link will take you to a non-Fannin Ltd. website.  Fannin Ltd. does not recommend, endorse or accept liability for sites controlled by third-parties.) 

 IE2022/056/00   

Date of Preparation: May 2022